Figure 4.

Existing approaches are lack of efficiency for nanoformulated drug screening. a,b) MTT assay failure to identify the different functional level of drugs after a short time treated. c) Annexin V‐APC/anti‐EGFR‐FITC flow cytometry analysis for VP16/LDH‐VP16 treated A549 cells for 2 and 6 h at various effective concentrations which are proven by 24 h MTT assays above. d) Annexin V‐APC flow cytometry analysis of Cur/SLN‐Cur treated HEpG2 cells at certain concentrations for 2 and 6 h. No significant difference could be observed in both the experiments. IE, LE, ME, and HE present ineffective, low, medium, and high efficacy, respectively.